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Using mice with targeted deletion of the glucocorticoid receptor (GR) Koenen et al.1 recently 
examined the cell types mediating the anti-arthritic effects of therapeutic glucocorticoids. In the 
serum transfer induced arthritis (STIA) model, rather than targeting immune cells they found that 
glucocorticoids exerted their effects through cells of the stromal compartment. This work 
highlights that despite being available for almost 70 years we are only now beginning to understand 
a medication that remains essential in the treatment of rheumatoid arthritis (RA).  
A range of elegant in vivo approaches were used to determine how glucocorticoids reduced joint 
inflammation. Bone marrow chimeras (generated by irradiating mice to destroy immune cells and 
then using donor cells to repopulate the marrow) and inducible genetic deletion of the GR (using a 
tamoxifen inducible Cre-Lox system) allowed mice to be generated with selective deletion of GR in 
either the haematopoietic or stromal compartment. The absence of the GR in haematopoietic cells 
had no impact on the ability of dexamethasone to suppress joint swelling and inflammation. 
However, absence of the GR in the stromal compartment rendered mice unresponsive to 
glucocorticoid effects on joint inflammation. 
This work follows on from the authors’ earlier work in an alternative mouse model of joint 
inflammation termed adjuvant induced arthritis (AIA).2 Interestingly in AIA mice they found that the 
anti-inflammatory effects of glucocorticoids were completely dependent on the presence of the GR 
in T cells, where IL-17 and Th17 cell suppression appeared to be major targets. Here, Tthere 
appeared to be no contribution from GR present in the stroma. The situation is further complicated 
in other inflammatory models, which suggest GR within macrophages are critical to the actions of 
glucocorticoids.3 ThisThese findings highlight that whilst illustrates that in different models of 
arthritis glucocorticoids have similar therapeutic effects on arthritisin different inflammatory 
models,  but that these effects arethese can be mediated by very different cell types. An unresolved 
question is how each of these mouse models translates into the clinical situation of RA and related 
joint diseases.  
Although not traditionally thought of as a major target of glucocorticoids the stroma is increasingly 
implicated as a target of glucocorticoid action in inflammatory arthritis. Mice with deletion of the GR 
in chondrocytes have exaggerated inflammation in both the AIA and STIA model highlighting a 
possible anti-inflammatory role for chondrocytic glucocorticoid signalling in arthritis.4 Somewhat 
paradoxically glucocorticoid signalling in osteoblasts appears to be pro-inflammatory with blockade 
of the GR resulting in reduced inflammation in STIA mice.5 In the paper by Koenen et al. the stromal 
cells appear to regulate inflammation through the by polarising recruitment of specific subsets of 
macrophages with towards a suppressive phenotype characterised by increased efferocytosis 
andincreased expression of anti-inflammatory markers. It is not clear how chondrocytes or 
osteoblasts exert their effects on inflammation. These results collectively indicate that several 
stromal cell types (synovial fibroblasts, chondrocytes and osteoblasts) can mediate effects of 
glucocorticoids on joint inflammation.  
An additional level of regulation of glucocorticoid action is the glucocorticoid metabolising enzyme 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme amplifies glucocorticoid 
signalling through the local production of active from inactiveactivation of glucocorticoids from 
inactive precursors. This enzyme is critical to the conversion of inactive glucocorticoids such as 
cortisone and prednisone to their active counterparts cortisol and prednisolone. Importantly 11β-
HSD1 does not metabolise dexamethasone. Mice defective in 11β-HSD1 develop exaggerated joint 
inflammation in acute and chronic model of arthritis.6,7 11β-HSD1 activity within macrophages 
appears to be critical in restraining inflammation in these models.8 It would be interesting to know 
whether the responses seen by Koenen et al. with dexamethasone are similar using glucocorticoids 
that are regulated by 11β-HSD1 such as those typically used to treat patients with RA.  
The novel finding that the stroma can be an important target opens up the prospect of developing 
medications that have the beneficial anti-inflammatory effects of glucocorticoids without the 
adverse actions. This long held goal has proven impossible to date. Earlier attempts to develop more 
selective glucocorticoids (selective glucocorticoid receptor agonists [SEGRAs]) resolved around the 
notion that the beneficial effects of glucocorticoids were due to the GR interfering with pro-
inflammatory signalling pathways as a monomer (termed repression) whereas the adverse effects 
were due to the GR binding as a dimer to DNA (termed activation).9 Koenen et al. examined this 
issue using mice that carried a mutated GR that was unable to form a dimer and as such could only 
‘repress’ and not ‘activate’. They found that, whilst the monomer was able to suppress pro-
inflammatory cytokines such as TNFα, IL-1β and IFNγ, the ability of the GR to dimerise was essential 
for the anti-inflammatory effects of glucocorticoids. This finding illustrates that the simplistic view of 
repression being good and activation bad is not tenable as a basis of developing SEGRAs. So should 
SEGRAs be developed on the basis of selective targeting of stromal cells? Perhaps tempering 
enthusiasm for a stromal targeted glucocorticoid like therapy is that the most prominent adverse 
effects of glucocorticoids such as osteoporosis, osteonecrosis, myopathy and skin thinning are 
manifested through actions on stromal cells.10 
A persisting question remains the applicability of these findings to people with RA and related 
conditions. It is unclear whether the animal models of arthritis individually or collectively mimic the 
biology seen in the clinic. It is possible that the most important targets of glucocorticoids change 
during the clinical course of inflammatory arthritis. The models employed so far focus on the short 
term relieve of joint inflammation by glucocorticoids rather than their long term impact on disease 
activity and joint integrity. Unfortunately the clever experimental techniques employed on mice by 
Koenen et al. cannot be used in humans to address the extent to which glucocorticoids target the 
stroma. What are now needed are novel translational approaches to study the actions of 
glucocorticoids in patients with RA. Without improved approaches to target glucocorticoids 
selectively to either the stromal or classical immune cells in patients with inflammatory arthritis it 
will be difficult to determine the relative contributions of each of these.  
Despite their vintage, glucocorticoids continue to give us surprises regarding how they work. This 
work by Koenen et al. uncovers facets of glucocorticoid action that suggest new options to optimise 
their effectiveness. 
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Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact 
allergy. 
